atherogenesis

(redirected from atherogenicity)
Also found in: Thesaurus, Medical.

ath·er·o·gen·e·sis

 (ăth′ər-ō-jĕn′ĭ-sĭs)
n.
Formation of atheromatous deposits, especially on the innermost layer of arterial walls.


ath′er·o·gen′ic (-jĕn′ĭk) adj.
ath′er·o·gen·i′ci·ty (-jə-nĭs′ĭ-tē) n.
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.atherogenesis - the formation of atheromas on the walls of the arteries as in atherosclerosisatherogenesis - the formation of atheromas on the walls of the arteries as in atherosclerosis
pathology - any deviation from a healthy or normal condition
Mentioned in ?
References in periodicals archive ?
Defining the atherogenicity of large and small lipoproteins containing apolipoprotein B100.
The diet-related atherogenicity found by Fornes et al.
In several studies it has been stated that LDL particles penetrate the endothelium more easily and thus atherogenicity increases as particle size decreases (24, 25).
The atherogenicity index (AI) and thrombogenicity index (TI) were calculated according to Ulbricht and Southgate [17]; the peroxidability index (PI) was calculated following Arakawa and Sagai [18]; and the hypocholesterolemic/hypercholesterolemic ratio (HH) was calculated in accordance with SantosSilva et al [19].
Antioxidative probiotic fermented goats' milk decreases oxidative stress-mediated atherogenicity in human subjects.
However, type-2 diabetic patients typically have a predominance of small, dense LDL particles, which possibly increases atherogenicity by a greater susceptibility to oxidation even if the absolute concentration of LDL cholesterol is not significantly increased.
Modification of low-density lipoproteins that increase its atherogenicity. N.
Dyslipidemia has been long recognized as a major biochemical event predisposing to atherogenicity and cardiovascular disease (CVD).
Therefore, it is worth assessing the efficacy against hyperglycemia, dyslipidemia, and atherogenicity in an animal model of type 1 diabetes.
Feng et al., "The relative atherogenicity of VLDL and LDL is dependent on the topographic site," Journal of Lipid Research, vol.
Atherogenic index of plasma (AIP) has emerged as a predictive marker for plasma atherogenicity [45].
In obese, insulin-resistant, nondiabetic subjects, salsalate reduced the atherogenicity of the lipid, lipoprotein, and apoprotein profile and insulin sensitivity [30, 31].